Small-molecule inhibition of inflammatory β-cell death

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Small-molecule inhibition of inflammatory β-cell death. / Lundh, Morten; Scully, S S; Mandrup-Poulsen, T; Wagner, B K.

I: Diabetes, Obesity and Metabolism Online, Bind 15 , Nr. 3, 09.2013, s. 176-84.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Lundh, M, Scully, SS, Mandrup-Poulsen, T & Wagner, BK 2013, 'Small-molecule inhibition of inflammatory β-cell death', Diabetes, Obesity and Metabolism Online, bind 15 , nr. 3, s. 176-84. https://doi.org/10.1111/dom.12158

APA

Lundh, M., Scully, S. S., Mandrup-Poulsen, T., & Wagner, B. K. (2013). Small-molecule inhibition of inflammatory β-cell death. Diabetes, Obesity and Metabolism Online, 15 (3), 176-84. https://doi.org/10.1111/dom.12158

Vancouver

Lundh M, Scully SS, Mandrup-Poulsen T, Wagner BK. Small-molecule inhibition of inflammatory β-cell death. Diabetes, Obesity and Metabolism Online. 2013 sep.;15 (3):176-84. https://doi.org/10.1111/dom.12158

Author

Lundh, Morten ; Scully, S S ; Mandrup-Poulsen, T ; Wagner, B K. / Small-molecule inhibition of inflammatory β-cell death. I: Diabetes, Obesity and Metabolism Online. 2013 ; Bind 15 , Nr. 3. s. 176-84.

Bibtex

@article{5dacf416595c4342b8b72c86d456a2a1,

title = "Small-molecule inhibition of inflammatory β-cell death",

abstract = "With the worldwide increase in diabetes prevalence there is a pressing unmet need for novel antidiabetic therapies. Insufficient insulin production due to impaired β-cell function and apoptotic reduction of β-cell mass is a common denominator in the pathogenesis of diabetes. Current treatments are directed at improving insulin sensitivity, and stimulating insulin secretion or replacing the hormone, but do not target progressive apoptotic β-cell loss. Here we review the current development of small-molecule inhibitors designed to rescue β-cells from apoptosis. Several distinct classes of small molecules have been identified that protect β-cells from inflammatory, oxidative and/or metabolically induced apoptosis. Although none of these have yet reached the clinic, β-cell protective small molecules alone or in combination with current therapies provide exciting opportunities for the development of novel treatments for diabetes.",

author = "Morten Lundh and Scully, {S S} and T Mandrup-Poulsen and Wagner, {B K}",

note = "{\textcopyright} 2013 John Wiley & Sons Ltd.",

year = "2013",

month = sep,

doi = "10.1111/dom.12158",

language = "English",

volume = "15 ",

pages = "176--84",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "3",

}

RIS

TY - JOUR

T1 - Small-molecule inhibition of inflammatory β-cell death

AU - Lundh, Morten

AU - Scully, S S

AU - Mandrup-Poulsen, T

AU - Wagner, B K

PY - 2013/9

Y1 - 2013/9

N2 - With the worldwide increase in diabetes prevalence there is a pressing unmet need for novel antidiabetic therapies. Insufficient insulin production due to impaired β-cell function and apoptotic reduction of β-cell mass is a common denominator in the pathogenesis of diabetes. Current treatments are directed at improving insulin sensitivity, and stimulating insulin secretion or replacing the hormone, but do not target progressive apoptotic β-cell loss. Here we review the current development of small-molecule inhibitors designed to rescue β-cells from apoptosis. Several distinct classes of small molecules have been identified that protect β-cells from inflammatory, oxidative and/or metabolically induced apoptosis. Although none of these have yet reached the clinic, β-cell protective small molecules alone or in combination with current therapies provide exciting opportunities for the development of novel treatments for diabetes.

AB - With the worldwide increase in diabetes prevalence there is a pressing unmet need for novel antidiabetic therapies. Insufficient insulin production due to impaired β-cell function and apoptotic reduction of β-cell mass is a common denominator in the pathogenesis of diabetes. Current treatments are directed at improving insulin sensitivity, and stimulating insulin secretion or replacing the hormone, but do not target progressive apoptotic β-cell loss. Here we review the current development of small-molecule inhibitors designed to rescue β-cells from apoptosis. Several distinct classes of small molecules have been identified that protect β-cells from inflammatory, oxidative and/or metabolically induced apoptosis. Although none of these have yet reached the clinic, β-cell protective small molecules alone or in combination with current therapies provide exciting opportunities for the development of novel treatments for diabetes.

U2 - 10.1111/dom.12158

DO - 10.1111/dom.12158

M3 - Journal article

C2 - 24003935

VL - 15

SP - 176

EP - 184

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 3

ER -

ID: 77964060

Biomedicinsk Institut